blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3512881

EP3512881 - TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  15.01.2021
Database last updated on 15.06.2024
FormerRequest for examination was made
Status updated on  21.06.2019
FormerThe international publication has been made
Status updated on  24.03.2018
Formerunknown
Status updated on  27.09.2017
Most recent event   Tooltip24.04.2024New entry: Application deemed to be withdrawn: despatch of communication + time limit 
Applicant(s)For all designated states
Nordic Nanovector ASA
Kjelsåsveien 168B
0884 Oslo / NO
[2019/30]
Inventor(s)01 / DAHLE, Jostein
Vallerveien 106 A
1344 Haslum / NO
02 / TURNER, Simon
c/o Nordic Nanovector ASA
Kjelsåsveien 168 B
0884 Oslo / NO
 [2019/30]
Representative(s)Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
[N/P]
Former [2019/30]Aera A/S
Gammel Kongevej 60, 18th floor
1850 Frederiksberg C / DK
Application number, filing date17768448.715.09.2017
[2019/30]
WO2017EP73336
Priority number, dateEP2016018919116.09.2016         Original published format: EP 16189191
EP2017016416431.03.2017         Original published format: EP 17164164
EP2017017064111.05.2017         Original published format: EP 17170641
EP2017017576813.06.2017         Original published format: EP 17175768
[2019/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018050851
Date:22.03.2018
Language:EN
[2018/12]
Type: A1 Application with search report 
No.:EP3512881
Date:24.07.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 22.03.2018 takes the place of the publication of the European patent application.
[2019/30]
Search report(s)International search report - published on:EP22.03.2018
ClassificationIPC:C07K16/28, C07K16/30, A61K51/10, A61K39/395, A61P35/00
[2019/30]
CPC:
A61K51/1096 (EP,KR,US); A61K51/1069 (EP,KR,US); A61K51/0482 (KR);
A61K51/1027 (EP,KR,US); A61P35/00 (EP,US); A61P35/02 (KR);
C07K16/2887 (EP,KR,US); C07K16/2896 (EP,KR,US); C07K16/3061 (EP,KR,US);
A61K2039/507 (EP,KR,US); A61K2039/545 (EP,KR,US); A61K2121/00 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/30]
TitleGerman:BEHANDLUNG VON NON-HODGKIN-LYMPHOM UNTER VERWENDUNG VON LILOTOMAB UND 177LU-LILOTOMAB-SATETRAXETAN[2019/30]
English:TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN[2019/30]
French:TRAITEMENT DE LYMPHOME NON HODGKINIEN À L'AIDE DE LILOTOMAB ET DE 177LU-LILOTOMAB SATETRAXETAN[2019/30]
Entry into regional phase15.03.2019National basic fee paid 
15.03.2019Designation fee(s) paid 
15.03.2019Examination fee paid 
Examination procedure15.03.2019Examination requested  [2019/30]
15.03.2019Date on which the examining division has become responsible
05.11.2019Amendment by applicant (claims and/or description)
18.01.2021Despatch of a communication from the examining division (Time limit: M08)
20.12.2021Reply to a communication from the examining division
23.04.2024Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
20.12.2021Request for further processing filed
20.12.2021Full payment received (date of receipt of payment)
Request granted
04.01.2022Decision despatched
Fees paidRenewal fee
27.09.2019Renewal fee patent year 03
28.09.2020Renewal fee patent year 04
27.09.2021Renewal fee patent year 05
27.09.2022Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
30.09.202307   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XAI]  - JOHAN BLAKKISRUD ET AL, "Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177 Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate", THE JOURNAL OF NUCLEAR MEDICINE, US, (20160901), vol. 58, no. 1, doi:10.2967/jnumed.116.180471, ISSN 0161-5505, pages 55 - 61, XP055420342 [X] 1-3,8,10,11,15-18 * whole document, especially the Abstract; page 56, second full paragraph; page 57, right-hand column, second paragraph; Tables 1-2; Figures 2-3 * [A] 19,20 [I] 4-7,9,12-14,21-24

DOI:   http://dx.doi.org/10.2967/jnumed.116.180471
 [XAI]  - JOHAN BLAKKISRUD ET AL, "Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177 Lu-Lilotomab Satetraxetan", THE JOURNAL OF NUCLEAR MEDICINE, US, (20160804), vol. 58, no. 1, doi:10.2967/jnumed.116.173922, ISSN 0161-5505, pages 48 - 54, XP055420455 [X] 1-4,8-11,16-18 * whole document, especially the Abstract; page 49, first full paragraph * [A] 19,20 [I] 5-7,12-15,21-24

DOI:   http://dx.doi.org/10.2967/jnumed.116.173922
 [XAI]  - Arne Kolstad ET AL, "PRE-DOSING WITH UNLABELLED ANTIBODY SIGNIFICANTLY INCREASES THE PHARMACOKINETIC EXPOSURE BUT PROTECTS AGAINST MYELOSUPPRESSION OF 177LU-LILOTOMAB IN NON-HODGKIN B-CELL LYMPHOMA PATIENTS", (20160609), page E1165, URL: https://learningcenter.ehaweb.org/eha/2016/21st/132714/arne.kolstad.pre-dosing.with.unlabelled.antibody.significantly.increases.the.html?f=m3e968, (20171101), XP055420926 [X] 1-4,9-11,14,16-18 * the whole document * [A] 19,20 [I] 5-8,12,13,15,21-24
 [XPI]  - Arne Kolstad ET AL, "A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THEACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINSTMYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMABSATETRAXETAN IN INDOLENT NHL PATIENTS", (20170518), page E1141, URL: https://learningcenter.ehaweb.org/eha/2017/22nd/180917/arne.kolstad.md.a.higher.amount.of.lilotomab.pre-dosing.increases.the.html, (20171101), XP055420928 [XP] 1-4,7,8,10,16-18 * the whole document * [I] 5,6,9,11-15,19-24
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.